Articles with "lifetime costs" as a keyword



Photo by thinkmagically from unsplash

Lifetime costs of invasive meningococcal disease: A Markov model approach.

Sign Up to like & get
recommendations!
Published in 2019 at "Vaccine"

DOI: 10.1016/j.vaccine.2019.09.060

Abstract: INTRODUCTION Invasive meningococcal disease (IMD) is an uncommon but life-threatening infectious disease associated with high sequelae rates in young children and an increased risk of mortality in adolescents and young adults. Funding decisions to reject… read more here.

Keywords: markov model; lifetime costs; disease; model ... See more keywords
Photo from wikipedia

Phase- and gender-specific, lifetime, and future costs of cancer

Sign Up to like & get
recommendations!
Published in 2021 at "Medicine"

DOI: 10.1097/md.0000000000026523

Abstract: Supplemental Digital Content is available in the text Abstract Valid estimates of cancer treatment costs are import for priority setting, but few studies have examined costs of multiple cancers in the same setting. We performed… read more here.

Keywords: lifetime costs; cancer; eur; future costs ... See more keywords

Costs associated with retinopathy of prematurity: a systematic review and meta-analysis

Sign Up to like & get
recommendations!
Published in 2022 at "BMJ Open"

DOI: 10.1136/bmjopen-2021-057864

Abstract: Objectives To review and analyse evidence regarding costs for retinopathy of prematurity (ROP) screening, lifetime costs and resource use among infants born preterm who develop ROP, and how these costs have developed over time in… read more here.

Keywords: review meta; meta analysis; lifetime costs; systematic review ... See more keywords
Photo by liskozac from unsplash

Lifetime Costs of Patients with Chronic Lymphocytic Leukemia

Sign Up to like & get
recommendations!
Published in 2017 at "Blood"

DOI: 10.1182/blood.v130.suppl_1.5621.5621

Abstract: Introduction: Patients with genomic aberrations del(11q), del(17p), and mutated IGHV in chronic lymphocytic leukemia (CLL) are at the highest risk for poor outcomes including shorter time to initial treatment, non-response to therapy (refractory disease), relapse,… read more here.

Keywords: response; lifetime costs; abbvie inc; economics ... See more keywords